An emerging AI startup from France, Bioptimus, successfully rounded up a $41million investment to build a novel AI model intended specifically for biological applications.
Taking Cue from OpenAI’s ChatGPT
Drawing inspiration from the acclaimed OpenAI’s ChatGPT, Bioptimus plans to adapt its impressive language modeling capabilities to the realm of biology. However, the task will not be free from hurdles due to the private nature and sensitivity of clinical data needed for training.
Ambition to Predict and Treat Diseases Better
Rooted in the ambitious goal of advancing our understanding of biology, the startup’s CEO, Jean-Philippe Vert, envisions a future in which simulations of biological systems provide precise predictions of disease outcomes and guide the formulation of more effective treatments.
France’s Flourishing AI Startup Scene
With AI startups blossoming nationwide, France has become an AI hub. High-profile funding rounds in recent months reinforce the nation’s growing reputation in this domain.
Bioptimus’ Rapid Growth and Link with Owkin
As a new player in the field, Bioptimus has shown remarkable growth since its inception. The company’s connections with AI and biotech juggernaut Owkin played a pivotal role in the startup’s swift success.
Funding to Bolster AI Platform and Collaborations
With the fresh influx of $41 million investments, Bioptimus plans to enhance its AI platform and broaden its alliances in the pharmaceutical and biotech arena. The firm also intends to release a new multi-modal foundational model, promising unprecedented applications for industries ranging from pharma to cosmetics.
The latest funding round was led by Cathay Innovation, with notable participants like Sofinnova Partners, Bpifrance, and Hitachi Ventures.
Original source: Read the full article on TechCrunch
